U.S., April 2 -- ClinicalTrials.gov registry received information related to the study (NCT06904131) titled 'A Phase I Clinical Trial of CAR-T Cells for Advanced Gynecological Solid Tumors' on March 10.
Brief Summary: Screening patients who meet the criteria for peripheral blood mononuclear cell (PBMC) isolation and cell preparation. Based on the status of cell preparation and mutual agreement between the researcher and the participant, the date of reinfusion (Day 0) is determined. From Day -5 to Day -3, the participant receives a conditioning regimen with cyclophosphamide and antithymocyte globulin. After recovery for two days (Day -2 and Day -1), on Day 0, the participant receives reinfusion of BZE2203 (dose determined according to the d...